<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20240217061029N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-03-04</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the Effect of Celery Capsules on the Quality of Sleep and Quality of Life of the Elderly</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the Effectiveness of the Traditional Persian Medicine Product based on the Apium Graveolens on the Sleep Quality and Quality of Life of the Community-Dwelling Elderly</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2024-04-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/75723</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Factorial, Purpose: Supportive, Randomization description: The Random Block Method will be Used to Allocate the Samples to Two Groups. For this Purpose, Patients will Receive Numbers from 1 to 70 According to Their Arrival. The Randomization Unit will be Individually and by Number with Blocks of 4 Persons. The Selection of the Group Type for Each Person will be done Through the Random Allocation 2 Software. In Order to Create a Random Sequence, Codes A and B will be Generated from the Desired Software, where Code A Mean the Application of the Intervention Group and Code B Mean the Application of the Control Group for Each Person. Finally, the Codes will be Placed in the Sealed Envelope and the Number of Each Patient will be Written on the Envelope. As Each Patient Enters, the Doctor will Open the Envelope and Apply the Desired Treatment, Blinding description: Medicine and Placebo Capsules will be Prepared Similar to Each Other, Even in Color and Packaging Container, and Coded before the Intervention by a Statistician Colleague, so that the Researcher and the Participant will not Know the Type of Intervention. (It Should be Noted that at First, the Objectives of the Study are Explained to all Patients and Written Consent will be Obtained from the Patients).</study_design>
      <phase>3</phase>
      <hc_freetext>Sleep Disorders in the Elderly.</hc_freetext>
      <i_freetext>Intervention 1: Intervention Group: due to the Lack of a Similar Study to Investigate the Effectiveness of Celery Plant on Sleep Quality, in Order to Determine the Drug Dose, First 10 Patients (Elderly 60 Years and Older with Poor Sleep Quality) were Selected as a Pilot, of which 5 They Received one 500 mg Celery Capsule (each Capsule Contains 250 mg Dry Celery Extract and 250 mg Corn Starch) and 5 other People, Two 500 mg Celery Capsules (each Capsule Contains 250 mg Dry Celery Extract and 250 mg Starch. Corn), they will Receive it Orally One Hour before Going to Sleep, then by Checking the Quality of Sleep at the End of the Fourth Week, the Dose of the Drug will be Determined. Intervention 2: Control Group: After Determining the Drug Dose in the Intervention Group, the Control Group will also Receive the same Dose, 500 mg Capsules Containing Corn Starch, One Hour before Going to Bed at Night and will be Examined at the End of the Fourth Week.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Scores of Questionnaires

When:
6 Months after the Results are Published

To whom:
Researchers Working in Academic and Scientific Institutions

Conditions:
Researchers Working in Academic and Scientific Institutions

Where to obtain:
hmtgh69@gmail.com
hamta.ghasemi@mazums.ac.ir

How to obtain:
Email to the Researcher

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamta Ghasemi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>2nd floor, Arshin Building 6, Haghighat Alley, Roudaki St., Amir Mazandarani Blvd</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815699761</zip>
        <telephone>+98 11 3336 9274</telephone>
        <email>hamta.ghasemi@mazums.ac.ir</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Yousofpoor</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Mazandaran University of Medical Sciences Headquarters, the Beginning of Valiasr Highway, Joibar Junction, Sari</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4815733971</zip>
        <telephone>+98 11 3304 4000</telephone>
        <email>m.yousofpoor@yahoo.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Desire to Participate in the Study and Give Informed Consent
Age 60 Years and Older
Low Quality of Sleep based on the Pittsburgh Sleep Quality Standard Questionnaire (Score 5 and above)
Not Having Cognitive Impairment and Speech Impairment (Getting a Score of 25 or Higher on the MMSE Test)
Not Having Diagnosed Mental Disorders that Interfere with Sleep, such as Restless Leg Syndrome, Obstructive Sleep Apnea, and Severe Depression and Anxiety Disorders, and are Treated with Relevant Drugs
Not Having Dependence on any Narcotic Drugs, Sleeping Pills and Alcohol and Not Consuming These Items in the Last Month
Not Having any History of Allergy to Celery and Similar Compounds
Not Taking Drugs that Affect the Sleep-Wake Cycle and Anticoagulants
Not Suffering from Physical Diseases that Affect the Sleep-Wake Cycle, such as Cancer, Liver and Kidney Disorders, Severe Anemia that Requires Treatment, and Coronary Heart Disorders.
Not having Epilepsy, History of low Blood Pressure
The Ability to Consume the Product Orally</inclusion_criteria>
      <agemin>60 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Not Taking Medicine for 5 Consecutive Nights or 10 Alternating Nights
Showing any Allergic Reaction to the Drug
Reluctance to Cooperate
Leaving the Study due to Reasons such as Death and Illness
Unfortunate Events such as the Death of Relatives</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group: due to the Lack of a Similar Study to Investigate the Effectiveness of Celery Plant on Sleep Quality, in Order to Determine the Drug Dose, First 10 Patients (Elderly 60 Years and Older with Poor Sleep Quality) were Selected as a Pilot, of which 5 They Received one 500 mg Celery Capsule (each Capsule Contains 250 mg Dry Celery Extract and 250 mg Corn Starch) and 5 other People, Two 500 mg Celery Capsules (each Capsule Contains 250 mg Dry Celery Extract and 250 mg Starch. Corn), they will Receive it Orally One Hour before Going to Sleep, then by Checking the Quality of Sleep at the End of the Fourth Week, the Dose of the Drug will be Determined.</i_keyword>
      <i_keyword>Control Group: After Determining the Drug Dose in the Intervention Group, the Control Group will also Receive the same Dose, 500 mg Capsules Containing Corn Starch, One Hour before Going to Bed at Night and will be Examined at the End of the Fourth Week.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The Sleep Quality Score of the Elderly based on the Pittsburgh Sleep Quality Standard Questionnaire. Timepoint: The Beginning of the Study (before the Start of the Intervention) and 4 Weeks after the Start of the Intervention. Method of measurement: Pittsburgh Sleep Quality Standard Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>The Score of the Quality of Life of the Elderly based on the Standard Questionnaire of the Quality of Life of the Elderly Lipad. Timepoint: The Beginning of the Study (before the Start of the Intervention) and 4 Weeks after the Start of the Intervention. Method of measurement: Standard Questionnaire of the Quality of Life of the Elderly Lipad.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-02-28</approval_date>
        <contact_name>Research Ethics Committee of Mazandaran University of Medical Sciences</contact_name>
        <contact_address>2nd Floor, Arshin Building 6, Haghighat Alley, Rudaki St.,Amir Mazandarani Blvd. Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
